Monday, November 20, 2000
As the number of antibody technology offerings has grown,
differentiating each from the competition has taken on more importance. For Abgenix Inc.,
staying competitive means obtaining access to technologies that complement or enhance its
antibody production platform, but not adding new platforms such as target discovery.
In the last two weeks, ABGX completed its acquisition of screening
company ImmGenics Inc. (Vancouver, B.C.) for $77 million in stock and announced its
acquisition of IntraImmune Therapies Inc. (Cambridge, Mass.) for $9 million in cash (see